Detail akcie Serina Therap Rg online

Business Summary: Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Serina Therapeutics Inc revenues increased from $56K to $130K. Net loss increased 15% to $11.3M. Revenues reflect PHARMACEUTICAL PREPARATIONS segment increase from $51K to $130K. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase from $3.9M to $11.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.51 to -$1.14.